Disease Synopsis
Overview
Drugs and Clinical Candidates
Clinical Trials (visual)
Clinical Trials (text)
Cell Line Models
Chemistry

Bowel Cancer - Overview - Disease Synopsis

Drugs & Clinical Candidates


21 drugs have received FDA approval for Bowel Cancer . Bevacizumab, Capecitabine, Cetuximab, Everolimus, Fluorouracil, Imatinib Mesylate, Ipilimumab, Irinotecan Hydrochloride, Leucovorin Calcium, Moxetumomab Pasudotox-tdfk, Nivolumab, Oxaliplatin, Panitumumab, Pembrolizumab, Ramucirumab, Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine, Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine, Regorafenib, Sunitinib Malate, Trifluridine and Ziv-Aflibercept
406 drugs have a clinical trial registered for Bowel Cancer.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Clinical Trials


There are 3608 clinical trials for Bowel Cancer,
1881 of which have one or more drug interventions,
1727 with no drug intervention.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Cell Line Models


There are 855 Cell Line Models for Bowel Cancer.

Source: COSMIC
(see details)

Chemistry


There are 69122 Compounds which have been tested in Bowel Cancer , 44441 <= 500nM potency.

Source: ChEMBL
(see details)

Mappings


Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Bowel Cancer:
Anus Neoplasms
Colonic Neoplasms
Colorectal Neoplasms
Colorectal Neoplasms, Hereditary Nonpolyposis
Digestive System Neoplasms
Gastrointestinal Neoplasms
Gastrointestinal Stromal Tumors
Jejunal Neoplasms
Rectal Neoplasms
Sigmoid Neoplasms

The following terms have been mapped from cancer.gov to Bowel Cancer:
Anal cancer
As adjuvant therapy in adults who have had a nephrectomy (surgery to remove the kidney) and have a high risk that the cancer will recur (come back)
Colorectal cancer
Colorectal cancer in adults and children 12 years and older. It is used alone or with ipilimumab to treat metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer that got worse after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan hydrochloride
Colorectal cancer in adults and children 12 years and older. It is used with nivolumab to treat metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer that got worse after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan hydrochloride
Colorectal cancer that has gotten worse after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan hydrochloride.????
Colorectal cancer that has metastasized
Colorectal cancer that has metastasized (spread to other parts of the body)
Colorectal cancer that has metastasized (spread to other parts of the body), including metastatic cancer that has recurred (come back) or has not gotten better with other chemotherapy
Colorectal cancer that has metastasized (spread to other parts of the body). It is used in adults who have already been treated with a fluoropyrimidine, oxaliplatin, irinotecan hydrochloride, and an anti-VEGF biologic therapy. Patients whose cancer does not have a mutation in the RAS gene should have also received an anti-EGFR therapy
Colorectal cancer that has metastasized (spread to other parts of the body). It is used in patients who have not gotten better with other treatments
Colorectal cancer that has metastasized (spread to other parts of the body). It is used in patients whose disease has not gotten better with other chemotherapy
Colorectal cancer that has metastasized (spread to other parts of the body). It is used:With FOLFOX combination chemotherapy as first-line therapy
Colorectal cancer that has metastasized. It is used with FOLFIRI in patients whose disease has gotten worse during or after treatment with bevacizumab, oxaliplatin, and a fluoropyrimidine
Colorectal cancer that is advanced
Colorectal cancer. It is used to treat stage III colorectal cancer in patients who have had surgery to remove the cancer. It is also used as first-line treatment of patients with metastatic colorectal cancer
Colorectal cancer. It is used with fluorouracil as palliative treatment in patients with advanced disease
Gastrointestinal stromal tumor (GIST)
Gastrointestinal stromal tumor (a type of stomach cancer). It is used in patients whose condition has become worse while taking imatinib mesylate or who are not able to take it
Gastrointestinal stromal tumor that is locally advanced, cannot be removed by surgery, or has metastasized (spread to other parts of the body). It is used in patients whose disease has not gotten better with imatinib mesylate and sunitinib malate
Hairy cell leukemia that has relapsed or is refractory (does not respond to treatment). It is used in adults who have been treated with at least two systemic therapies, including a purine nucleoside analog
Lesions that sometimes lead to anal, cervical, vaginal, or vulvar cancer
Pancreatic cancer, gastrointestinal cancer, and lung cancer (certain types). It is used in adults with progressive neuroendocrine tumors that cannot be removed by surgery, are locally advanced, or have metastasized (spread to other parts of the body)
Stage III colon cancer. It is used as adjuvant therapy in patients who have had surgery to remove the cancer